NeoStem Provides Updates and Reports Year End Results
Posted: March 20, 2012 at 7:27 pm
NEW YORK, March 20, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or "the Company") is a leader in the cell therapy industry, developing cell based therapeutics supported by the Company's expertise in contract manufacturing. This strategic combination and depth of experience in cell therapy development and manufacturing provide NeoStem with unique capabilities to develop its own cell therapies and that sets the Company apart from others in the cell therapy landscape. 2011 represented a major year of strategic transition for NeoStem, and the Company plans to build upon that in 2012 and in the years ahead.
NeoStem reported its audited results for 2011. Consolidated revenues for the year ended December 31, 2011 were $73.7 million compared to $69.8 million for 2010. The Company's consolidated net loss for 2011 was $56.6 million, which included $10.3 million of non-cash equity-based compensation expense, $19.4 million of goodwill impairment charges and $9.0 million of depreciation and amortization. Overall, the Company's consolidated cash loss for 2011 was $15.5 million (see reconciliation below). Net loss attributable to NeoStem common shareholder interests for 2011 was $47.8 million, or $0.54 per share.
As of December 31, 2011, the Company had consolidated cash and cash equivalents of $12.7 million, and an additional $2.5 million in cash held in escrow (classified in Other Assets).
NeoStem believes that the opportunities that exist today in cell therapy are robust and growing despite a persistently difficult financial environment, making this an opportunistic time to pursue the monetization of the Company's 51% ownership of Suzhou Erye Pharmaceutical Co., Ltd. and bolster its cell therapy business. In June 2011, the Company engaged a financial advisor to lead the effort to pursue the possible divestiture of the Company's interest in Erye. Marketing efforts are underway and have generated interest from both financial and strategic buyers.
On the therapeutics side of the business NeoStem now has a pipeline of assets that includes Amorcyte (Phase 2 trial for preservation of heart function after a heart attack), Athelos (physician sponsored Phase 1 trials for a range of auto-immune conditions) and pre-clinical development work on its VSEL(TM) technology. The Company's most advanced asset is AMR-001 for the treatment of acute myocardial infarction for which enrollment for a Phase 2 study in the United States commenced in January. The study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of infarct-related artery infusion of AMR-001, an autologous bone marrow derived cell therapy enriched for CD34+ cells. AMR-001 is administered 5 to 11 days post-stent placement in patients diagnosed with an ST segment elevation myocardial infarction ("STEMI") with ejection fraction less than or equal to 48%. The study will include 160 subjects, age 18 and older, randomized 1:1 between treatment and control. The manufacturing, product supply, and logistics for the trial will be supported by Progenitor Cell Therapy, LLC, NeoStem's contract manufacturing company.
Amorcyte currently has ten activated clinical trial sites for its Phase 2 AMI clinical trial with the initial patients enrolled. Trial enrollment is expected to be completed in approximately one year with data read out six months following the last treated patient. The Amorcyte franchise is supported by a strong patent portfolio which includes both composition of matter and methods of treatment around use of these hematopoietic stem cells for treatment of cardiac ischemia and other ischemic tissue that result from vascular insufficiency. The Company sees Amorcyte as a pipeline of therapeutics with potential in multiple indications from STEMI to congestive heart failure and other related vascular insufficiencies. The Amorcyte product addresses both an unmet medical need and a large potential market.
"One of the most important attributes of AMR-001 is that it's 'natural.' We are enhancing the body's normal and natural response to ischemic injury," said Dr. Robin Smith, CEO of NeoStem. "Ample historical evidence, published literature and our own compelling Phase 1 data give us confidence that this product will ultimately make it to the marketplace. Our next most advanced asset is held by Athelos Corporation, (a NeoStem company, partnered with Becton, Dickinson and Company) which is developing a novel T-cell platform for immunological disorders. The Athelos T-cell technology represents an innovative approach to restoring immune balance with potential applications in graft vs. host disease (GvHD), solid organ transplant (SOT) and autoimmune diseases, such as asthma and diabetes. Multiple physician sponsored phase 1 studies are expected to report results that will be used to determine the direction of clinical development.
"NeoStem is also developing pre-clinical assets, including its VSEL(TM) Technology platform for regenerative medicine, which NeoStem believes is an endogenous pluripotent non-embryonic cell that has the potential to change the paradigm of cell therapy as we know it today. These activities have received awards in excess of $2.5 million which funds support the work of prestigious researchers who are pioneering this science with NeoStem.
"Behind the development of these therapeutic assets is the NeoStem cell therapy contract manufacturing business (PCT) which itself continues to grow. New clients have engaged PCT to assist them in the development of their products, including a global, diversified healthcare company who recently selected PCT to provide stem cell processing in our two GMP manufacturing facilities in the United States (California and New Jersey). PCT's prominence in the marketplace continues to grow and that is reflected by both client satisfaction and the revenues the company generates.
"As we look to the year ahead, we are excited on multiple fronts. Our capital preservation efforts are now bearing fruit as our cash burn rate is in-line with our peers. We expect to continue to carefully invest our capital in projects that meet our internal rate of return hurdle and risk parameters. We believe the PCT and Amorcyte acquisitions have created true value for our shareholders and we look forward to demonstrating that as these assets reach their respective value inflection points. We see the unmet medical need in cardiology and the treatment burden associated with chronic diseases as representing a significant challenge to modern society. We believe that cell therapy holds many of the solutions to the health crisis that societies face and have the potential to create real pharmacoeconomic benefit as well as shareholder value for our company.
See the original post here:
NeoStem Provides Updates and Reports Year End Results
- CAR T-Cell Immunotherapy for ALL - National Cancer Institute - October 27th, 2015
- Gene Therapy and Cell Therapy Defined | ASGCT - American ... - October 20th, 2015
- StemCell Therapy MD - October 3rd, 2015
- Stem Cell Therapy in Mexico - May 8th, 2015
- Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells Application In Patients - Video - May 1st, 2015
- Platelet Rich Plasma Injections For Chronic Pain Relief May Help You Avoid Sugery - Video - May 1st, 2015
- Stem Cell Treatment for COPD | StemRx Bioscience Solutions - Video - April 25th, 2015
- Stem Cell Therapy Market in Asia-Pacific to 2018 - Video - April 22nd, 2015
- Phytoscience Philipine celebrity Share good effect of stem cell Therapy - Video - April 18th, 2015
- STEM CELL therapy incredible results for severe MS - Video - April 18th, 2015
- Clinical Benefits of Stem Cell Therapy - Video - April 18th, 2015
- NYC Health & Longevity Center Now Offering Stem Cell Therapy to Avoid Joint Replacement - April 13th, 2015
- U.S. Stem Cell Clinic: What Conditions Can Be Treated? - Video - April 12th, 2015
- Stem Cell Therapy In USA - April 12th, 2015
- Stem Cell Therapy for Pain - Now Available at Columbia Pain Management - Video - April 11th, 2015
- What is Stem Cell Therapy- Trinity Spine and Wellness Center New Port Richey - Video - April 11th, 2015
- U.S. Stem Cell Clinic: How long will my recovery take? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: Stem Cell Banking - Video - April 11th, 2015
- U.S. Stem Cell Clinic: What is Stem Cell Therapy? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: How is Stem Cell Therapy Performed? - Video - April 11th, 2015
- U.S. Stem Cell Clinic: When should I expect to see results? - Video - April 11th, 2015
- Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center - Video - April 3rd, 2015
- Induced Pluripotent Stem Cell (iPSC) Industry Complete Report 2015 - 2016 - April 3rd, 2015
- Stem Cell Therapy for Neuromuscular Diseases | InTechOpen - March 31st, 2015
- Arizona Pain Stem Cell Institute Now Offering Stem Cell Therapy to Help Patients Avoid Hip and Knee Replacement - March 31st, 2015
- Center of Regenerative Orthopedics in South Florida Now Offering Stem Cell Therapy to Help Avoid Hip and Knee ... - March 31st, 2015
- Ask Dr. Lemper | Stem Cell Therapy Treatments - Video - March 29th, 2015
- No stem cell treatment for public servant's dodgy knee - March 26th, 2015
- Stem Cell Therapy - Lilli Donovan - Video - March 25th, 2015
- Stem Cell Research - Stem Cell Treatments - Treatments ... - March 25th, 2015
- What is "Stem cell therapy" ? | Steps in PRP Treatment : TV5 News - Video - March 23rd, 2015
- Stem cell clinics under govt scanner - March 22nd, 2015
- SuperCells at Centre for Life - Video - March 21st, 2015
- Knee arthritis 3 years after stem cell therapy by Harry Adelson, N.D. - Video - March 21st, 2015
- Stem Cell Injection Treatment Stem Cell Therapy - Video - March 21st, 2015
- stem cell therapy di indonesia Jakarta tangerang serpong bsd bintaro - Video - March 21st, 2015
- The Alpha Clinic for Cell Therapy and Innovation | City of Hope - Video - March 20th, 2015
- Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM - Video - March 20th, 2015
- Stem cell therapy may help treat type 2 diabetes - March 20th, 2015
- CAR T-Cell Therapy - Nebraska Medicine - Video - March 18th, 2015
- Stem Cell Therapy- Sci Video2 - Video - March 18th, 2015
- Stem Cell Therapy Now Being Offered for NonHealing Wounds at Telehealth's Three Regenerative Medicine Clinics - March 17th, 2015
- Stem Cell Research & Therapy | Full text | Amnion-derived ... - March 15th, 2015
- High-Dose Immunosuppressive Therapy and Autologous ... - March 15th, 2015
- Miracle stem cell therapy reverses multiple sclerosis - Video - March 14th, 2015
- Hip and shoulder arthritis six months after bone marrow stem cell therapy by Harry Adelson ND - Video - March 13th, 2015
- Stem Cell Therapy Network - Video - March 12th, 2015
- Stem Cell Therapy Cream - Video - March 9th, 2015
- BioLogic Stem Cell Therapy Cream - Video - March 8th, 2015
- World Over - 2015-02-26 - Vatican latest, ISIS, stem cell therapy, Ray Flynn with Raymond Arroyo - Video - March 8th, 2015
- Shoulder Labral Tear Repair Using Stem Cell Therapy - Orthopedic Surgeon, Dr. Wade McKenna - Video - March 6th, 2015
- What Makes Riordan-McKenna Institute Different? Stem Cell Therapy for Orthopedics - Video - March 6th, 2015
- Overcoming Knee Replacement Surgery Faster Using Amniotic Tissue-Enhanced Stem Cell Therapy - Video - March 6th, 2015
- Stem Cell Therapy in Osteo Arthritis Knee - Video - March 6th, 2015
- stem cell therapy helps avoiding knee surgery - Video - March 6th, 2015
- Stem cell therapy in AKI Dr Mohamed Kamal - Video - March 6th, 2015
- Stem Cell Therapy for Bone Fractures - Board-Certified Orhopedic Surgeon, Wade McKenna DO - Video - March 5th, 2015
- Procedure Overview - The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video - March 5th, 2015
- Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video - March 5th, 2015
- Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson - Video - March 1st, 2015
- Animal cells for a younger you - March 1st, 2015
- 'Miracle' stem cell therapy reverses multiple sclerosis - March 1st, 2015
- Stem cell therapy a boon to Parkinson's patients - February 27th, 2015
- Stem Cell Research & Therapy | Full text | Aromatic ... - February 23rd, 2015
- Why Stem Cell Therapy? - Video - February 22nd, 2015
- What is Bone Marrow Aspirate Concentrate (BMAC) in Stem Cell Therapy? - Video - February 21st, 2015
- Dr Ellis hosts seminar on Stem Cell Therapy & Facial Rejuvenation - Video - February 17th, 2015
- Hip arthritis 3.5 years after stem cell therapy by Harry Adelson, N.D. - Video - February 16th, 2015
- How about Stem Cell Therapy for LBD, Nova Cells Institute stem cells - Video - February 14th, 2015
- Stem Cell Therapy for Erectile Dysfunction - Alvarado Hospital - Video - February 14th, 2015
- Cell Therapy may have just raised $1M, but will crowdfunding have a lasting place in biotech? - February 10th, 2015
- International Stem Cell completes cell bank manufacturing for Parkinson's disease clinical trial - February 4th, 2015
- Tampa stem cell clinic is long on promises, not evidence - February 1st, 2015
- Denver Regenerative Medicine - What is regenerative medicine? - Video - January 30th, 2015
- Cell Trials - January 26th, 2015
- "She's Happy" RMG's next Stem Cell Miracle - Video - January 21st, 2015
- Nutech Mediworld - Pioneering human embryonic stem cell therapy - Video - January 21st, 2015
- Stem Cell Therapy | Recent Strides Quell Stem Cell Debate - Video - January 20th, 2015
- Dr Sherif Stem cell therapy on OA - Video - January 18th, 2015
- Live100 Hospitals - Stem Cell Therapy - Video - January 16th, 2015